Home/Pipeline/NanoDisc Platform Programs

NanoDisc Platform Programs

Autoimmune Diseases (Type 1 Diabetes, Celiac, Lupus, MS)

PreclinicalActive

Key Facts

Indication
Autoimmune Diseases (Type 1 Diabetes, Celiac, Lupus, MS)
Phase
Preclinical
Status
Active
Company

About EVOQ Therapeutics

EVOQ Therapeutics is a private, preclinical-stage biotech founded in 2016, headquartered in Ann Arbor, Michigan, with a presence in San Diego. The company's breakthrough is the NanoDisc technology, a targeted antigen delivery system that aims to treat autoimmune diseases at their root cause by reprogramming the immune system. EVOQ has established significant partnerships with major pharmaceutical companies like Sanofi and Gilead and is advancing eight programs toward clinical development. Its approach promises enhanced efficacy with simple subcutaneous administration.

View full company profile